Experimental COVID-19 therapy targets cancer patients
NCT ID NCT03305341
First seen Jun 11, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This early-stage trial tests a biologic treatment for 20 people with moderate COVID-19 who also have controlled cancer. The treatment aims to help the immune system recognize and kill the virus. Researchers will check if the virus clears and if the immune response improves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medicine Invention Design Incorporation (MIDI) - IORG0007849
North Bethesda, Maryland, 20852, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.